Serial Urinary C-C Motif Chemokine Ligand 14 and Risk of Persistent Severe Acute Kidney Injury
Prowle, John R. (Queen Mary University of London)
Artigas Raventós, Antoni (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Bagshaw, Sean M. (University of Alberta)
Forni, Lui G. (University of Surrey and Royal Surrey County Hospital NHS Foundation Trust, Guildford)
Heung, Michael (University of Michigan)
Hoste, Eric (Ghent Universit)
Marlies, Ostermann (King's College London)
Koyner, Jay L. (University of Chicago)
Chawla, Lakhmir S (Veterans Affairs Medical Center)
Kampf, J. Patrick (Astute Medical (Estats Units d'Amèrica))
Kwan, Thomas (University of Pittsburgh)
McPherson, Paul (Astute Medica (Estats Units d'Amèrica))
Kellum, John A. (University of Pittsburg)

Date:	2023
Abstract:	Retrospective observational study. Data derived from two multinational ICU studies (Ruby and Sapphire). Critically ill patients with early stage 2-3 AKI. None. We analyzed three consecutive uCCL14 measurements at 12-hour intervals after diagnosis of stage 2-3 AKI by Kidney Disease Improving Global Outcomes criteria. Primary outcome was persistent severe AKI, defined as 72 consecutive hours of stage 3 AKI, death, or receipt of dialysis prior to 72 hours. uCCL14 was measured using the NEPHROCLEAR uCCL14 Test on the Astute 140 Meter (Astute Medical, San Diego, CA). Based on predefined, validated cutoffs, we categorized uCCL14 as: low (≤ 1. 3 ng/mL), medium (> 1. 3 to ≤ 13 ng/mL), or high (> 13 ng/mL). Seventy-five of 417 patients with three consecutive uCCL14 measurements developed persistent severe AKI. Initial uCCL14 category strongly correlated with primary endpoint and, in most cases (66%), uCCL14 category was unchanged over the first 24 hours. Compared with no change and accounting for baseline category, decrease in category was associated with decreased odds of persistent severe AKI (odds ratio [OR], 0. 20; 95% CI, 0. 08-0. 45; p < 0. 001) and an increase in category with increased odds (OR, 4. 04; 95% CI, 1. 75-9. 46; p = 0. 001). In one-third of patients with moderate to severe AKI uCCL14 risk category altered over three serial measurements and such changes were associated with altered risk for persistent severe AKI. Serial CCL-14 measurement may detect progression or resolution of underlying kidney pathology and help refine AKI prognosis.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Acute kidney injury ; Biomarkers ; C-C motif chemokine ligand 14 ; Critical illness ; Prognosis
Published in:	Critical Care Explorations, Vol. 5 (march 2023) , ISSN 2639-8028

DOI: 10.1097/CCE.0000000000000870
PMID: 36875557

11 p, 983.1 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles